摘要
[目的]观察胃癌患者治疗前后Kaiso、Flotillin-1 mRNA表达变化,探讨黄芪建中汤防治胃癌的机制研究。[方法]50例符合诊断标准、纳入标准、排除标准的胃癌患者按就诊顺序1:1分为对照组与治疗组,对照组给予化疗药物治疗,治疗组给予黄芪建中汤联合化疗药物治疗,2组均为3个疗程。应用Karnofsky评分记录2组患者治疗前后生活质量积分变化,应用实时荧光定量PCR技术检测2组治疗前、后Kaiso、Flotillin-1的表达变化。[结果]全部病例完成临床观察,治疗组完全缓解0例、部分缓解9例、稳定10例、进展6例,总有效率为76%;对照组完全缓解0例、部分缓解8例、稳定8例、进展9例,总有效率为64%;2组比较,差异有统计学意义(P<0.05)。治疗前Kaiso、Flotillin-1表达呈上升趋势;治疗后,治疗组Kaiso、Flotillin-1表达呈下降趋势,较治疗前差异有统计学意义(P<0.05)。对照组Kaiso、Flotillin-1表达较治疗前无明显变化。[结论]黄芪建中汤可能通过调控Kaiso、Flotillin-1表达水平,有效缓解胃癌患者临床症状,发挥协同治疗作用。
[Objective]To explore the effect of Huangqijianzhong Decoction on the expression of Kaiso and Flotillin-1mRNA in gastric cancer patients and to investigate the underlying mechanisms.[Methods]Fifty patients who met the diagnostic criteria,inclusion criteria and exclusion criteria of gastric cancer were divided into control group and treatment group according to the order of treatment.The control group was given chemotherapy drug,and the treatment group was given Huangqijianzhong decoction combined with chemotherapy drug.The treatment lasted 3courses.The life quality score was recorded according to Karnofsky score before and after treatment.The expression of Flotillin-1and Kaiso were detected by realtime PCR.[Results]All the patients completed the clinical observation.The total efficiency was 76% in treatment group and 64% in control group.There was statistical significant difference between the two groups（P0.05）.Before the treatment,the expression of Flotillin-1and Kaiso were increased.Then the expression of Flotillin-1and Kaiso were decreased after the treatment.The expression of Kaiso and Flotillin-1in the control group had no significant change.[Conclusion]Huangqijianzhong Decoction can effectively improve clinical symptoms of gastric cancer by regulating the expression of Kaiso and Flotillin-1.
出处
《中国中西医结合消化杂志》
CAS
2016年第2期108-111,115,共5页
Chinese Journal of Integrated Traditional and Western Medicine on Digestion
